If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
178
results.
Updated on
21/02/2026 [07:40:00]
Results 125 to 150 of 178
Absstract of: WO2025185743A1
Use of N-oleoylethanolamide(OEA) or a microbiota OEA producer, such as Eubacterium rectale, in the preparation of medicament for the treatment of irritable bowel syndrome (IBS).
Absstract of: WO2025188870A1
Provided herein are methods of identifying a subject as having an inflammatory bowel disorder, wherein a method includes (a) determining a level of NXPE1 in a biological sample from the subject; and (b) comparing the level of NXPE1 in the biological sample to a reference level, wherein the presence of a level of NXPE1 in the biological sample above the reference level indicates that the subject has an inflammatory bowel disorder.
Absstract of: WO2025186390A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Absstract of: US2025281553A1
Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
Absstract of: WO2024094817A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Absstract of: EP4614151A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Absstract of: CN120605330A
The invention discloses a novel application of a transient receptor potential cation channel subgroup C member 4 (TRPC4) inhibitor in preparation of a medicine for preventing or treating inflammatory bowel disease (IBD). The research finds that in a colitis mouse model, the enteritis symptom of the colitis mouse can be obviously improved by systemic gene knockout of TRPC4 or application of a TRPC4 inhibitor. Therefore, the TRPC4 is related to the disease progress of the colitis, and the TRPC4 can be used as a biomarker for screening patients and predicting the curative effect.
Absstract of: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Absstract of: CN120590530A
The invention discloses a TL1A targeting antibody and an application thereof. The antibody provided by the invention can be used for blocking the interaction between TL1A and DR3, is helpful to achieve the purpose of intervention from the early stage of inflammation, inhibits immune cells such as effector T cells from releasing cytokines for proinflammatory reaction, and provides more possibilities for treatment methods of IBD patients or other TL1A related diseases.
Absstract of: CN120594728A
The invention discloses a method for determining the content of organic acid metabolites of dark plums in colon tissue and application. The determination method comprises the following steps: (1) adding sterilized normal saline into colon tissues, grinding, adding methanol, continuously grinding, centrifuging, taking a supernatant, adding methanol for vortex, centrifuging, and finally adding water for vortex to obtain a sample solution to be detected; (2) a high performance liquid chromatography-mass spectrometry method is adopted, citric acid, malic acid and quinic acid standard substances are used for drawing standard curves of the three organic acids, citric acid adopts a positive ion mode, and malic acid and quinic acid adopt a negative ion mode; and (3) detecting the sample to be detected by adopting the same method, and calculating the concentrations or contents of the three organic acid metabolites (citric acid, malic acid and quinic acid) according to the standard curve. The method is simple and high in sensitivity, and can be used for researching the mechanism of the smoked plum acting on the ulcerative colitis.
Absstract of: WO2025184435A1
The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.
Absstract of: WO2025181327A1
The present invention relates to a method for determining a need for adjustment of parenteral supplementation, risk of developing acid-base imbalance, and monitoring development of acid-base imbalance in a subject receiving parenteral supplementation and having intestinal insufficiency, such as short bowel. In particular, the present invention relates to determining urinary net acid excretion (NAE) for evaluating acid-base imbalances in subjects having intestinal insufficiency, such as short bowel, in order to determine risk of developing and/or monitoring development of acid-base imbalance, as well as adjustment of parenteral supplementation.
Absstract of: WO2025181330A1
The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).
Absstract of: US2025277269A1
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Absstract of: EP4610657A1
Provided are a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
Absstract of: US2025243548A1
Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.
Absstract of: MX2025009868A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.
Absstract of: CN120577530A
The invention discloses a therapeutic target for inflammatory bowel disease and application thereof. Research finds that NO can be combined with an enzyme active site of a CYP450 family member, so that the activity of the CYP450 family member is inhibited, finally generation of a pathogenic factor GM-CSF is inhibited, and enteritis is relieved. On the basis, an inflammatory bowel disease product, a kit and an analysis system are developed. According to the invention, a new strategy can be provided for preventing, detecting and treating intestinal inflammatory diseases, and the intestinal homeostasis imbalance can be effectively improved.
Absstract of: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Absstract of: CN120559221A
The invention discloses application of Gli1 + interstitial cells or SMOC2 protein thereof in diagnosis, treatment and prognosis evaluation of Crohn disease intestinal stenosis. The invention provides application of Gli1 + interstitial cells and SMOC2 protein as targets in preparation of a diagnostic kit or a therapeutic drug for Crohn disease fibrostenosis, and further provides the diagnostic kit for Crohn disease fibrostenosis and the therapeutic drug for Crohn disease fibrostenosis. Meanwhile, the invention further provides application of the reagent for detecting the expression quantity of the SMOC2 in preparation of the kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis and the corresponding kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis. The invention discusses the effect of the Gli1 + interstitial cells in the attack of intestinal fibrostenosis, evaluates the potential of the Gli1 + interstitial cells as a diagnosis and treatment target, and provides a new thought for the treatment of Crohn disease intestinal stenosis.
Absstract of: CN120550120A
The invention discloses an application of inhibiting CD4 + T cell aging in preparation of a medicine for slowing down the progress of elderly ulcerative colitis. The invention provides an application of a substance for inhibiting the aging of CD4 + T cells in preparation of a product with at least one of the following functions: preventing senile ulcerative colitis; treating the elderly ulcerative colitis; the progress of elderly ulcerative colitis is relieved; diseases caused by aging of CD4 + T cells can be prevented or treated. A mouse model of specific knockout of the CD4 + T cell METTL3 is constructed, and it is found that specific knockout of the CD4 + T cell METTL3 can significantly inhibit the aging phenotype of the CD4 + T cell, so that DSS-induced mouse colitis and T cell adoptive transfer mediated enteritis are relieved. By improving CD4 + T cell senescence, UC, especially the progress of elderly UC, is relieved.
Absstract of: CN120554525A
The invention provides a fusion protein as well as a preparation method and application thereof. Specifically, the fusion protein disclosed by the invention has a structure as shown in a formula I: in the formula, Z0 is a tag sequence for purposes of purification, separation and the like; z1 is a human serum amyloid A protein fragment; l1 is none or a joint; z2 is fluorescent protein. The invention provides a preparation method and application of the fusion protein, the method is high in yield and free of risks of cross infection, gene mutation and the like, and the Clover-SSA1 protein prepared through the method can be used in the research fields of disease diagnosis, drug screening, biomarkers and the like, namely Z0-Z1-L1-Z2 (I).
Absstract of: CN120549942A
According to the application, the application of the taurocholic acid (TCA) in the medicine for preventing and treating the colitis injury is found and proved, the clinical effect is remarkable, the TCA with a proper concentration can promote the growth of Caco-2 cells and can relieve inflammation caused by LPS, but the TCA with a high concentration can inhibit the growth of the Caco-2 cells. Through intragastric administration of TCA, mouse colitis induced by escherichia coli can be relieved, TCA with a proper concentration can treat colitis, and through in-vitro and in-vivo dual verification, the optimal concentration of TCA in the aspect of treating colitis and the treatment effect of TCA on colitis caused by pathogenic escherichia coli are determined. Theoretical support is provided for medicine development of TCA in the aspect of treating intestinal inflammation, and the TCA is worthy of being widely popularized and used clinically.
Absstract of: CN120555244A
The invention discloses pathogenic escherichia coli which is named as Escherichia coli.NM3A and is preserved in China Center for Type Culture Collection on April 14, 2025, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No: 34176. According to the invention, a mouse colitis model can be established by using the calf-derived Escherichia coli.NM3A, and the new Escherichia coli.NM3A separated from calf feces can be proved to have a pathogenic gene through whole genome sequencing and virulence gene PCR (Polymerase Chain Reaction) detection; a mouse inflammation model is established by feeding the Escherichia coli.NM3A into the calf excrement, and the new Escherichia coli.NM3A separated from the calf excrement can be proved to have pathogenicity and can cause mouse colitis.
Nº publicación: US2025271429A1 28/08/2025
Applicant:
KUENSTNER JOHN TODD [US]
GALARNEAU JEAN MICHEL [CA]
Kuenstner John Todd,
Galarneau Jean-Michel
Absstract of: US2025271429A1
A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
BOPI
Electronic site
